Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

86.15 -2.29 (-2.59%)
Streaming Delayed Price Updated: 1:17 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Palvella Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology
Presentation to highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN™ rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations 
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.